30Jan

OGT unveils reliable somatic CNV detection for CLL with new NGS panel

Oxford, UK – 14 January 2020. Oxford Gene Technology (OGT), A Sysmex Group Company, is excited to announce the launch of its SureSeq CLL + CNV Panel — the company’s latest high-quality, next-generation sequencing (NGS) offering for research into Chronic Lymphocytic Leukaemia (CLL). The SureSeq CLL + CNV Panel fulfils the desire for reliable copy number variation (CNV) detection by NGS, including trisomy 12 and loss of heterozygosity (LOH), as well as somatic variants, even at low allele frequency. The panel, which has been tested to show excellent concordance with array data, can detect both small and large CNVs at 10% minor allele frequency (MAF), SNVs and indels down to 1% MAF and LOH at 5-10Mb.

 

The comprehensive panel covers all the most up-to-date, evidence-based genes and genomic aberrations for CLL and will enable laboratories to simplify their laboratory workflow by replacing multiple assays with a single one.

 

CLL is the most common type of leukaemia in adults and is associated with chromosomal aberrations ranging from somatic variants, to small and large CNVs, including trisomies. This complex genetic heterogeneity combined with a lack of sensitive and reliable NGS solutions has meant that currently scientists need to employ multiple methods to build a genomic profile of CLL samples.

 

One area in particular where NGS has traditionally struggled, is in the detection of CNVs, which can occur in important tumour suppressor genes, such as TP53. Additional techniques such as microarray, karyotyping or fluorescence in situ hybridisation (FISH) are often required to detect these CNVs and structural abnormalities, such as loss of heterozygosity (LOH) and trisomy 12.

 

The SureSeq CLL + CNV Panel was designed in collaboration with recognised cancer experts, as Emma Shipstone, Executive VP Marketing at OGT, highlights: “Having input from experienced cancer labs was instrumental in getting the design of the SureSeq CLL + CNV Panel spot on. This is CNV detection done well, yielding excellent data quality. This one assay can now replace the multiple assays historically necessary for the genomic profiling of CLL samples.”

 

For researchers, the single NGS panel simplifies the workflow and consolidates the profiling of the wide variety of genomic changes into a single analysis. Reliable data analyses can be carried out with OGT’s popular and easy-to-use Interpret software, a complementary and powerful software solution for accurate identification and visualisation of all variants including CNVs.

 

For more information please visit https://www.ogt.com/CLL.

 

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.

T: +44 (0) 1865 856800 ; F: +44 (0) 1865 848684

E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech

Related

FDA grants de novo designation for OGT’s AML/MDS FISH probes

Clearance enables accurate and easy-to-interpret AML and MDS detection with reduced validation burde...

Read More >

SpeeDx and Diagen sign new distribution agreement for Scandinavia

SYDNEY, AUSTRALIA – (Sept 19, 2017). SpeeDx Pty, Ltd. has announced a distribution agreement with D...

Read More >

EKF expands geographical reach of PCT test for early sepsis detection

Cardiff, UK – 2nd May 2017 – EKF Diagnostics, the global in vitro diagnostics company, announces t...

Read More >

Biofortuna expands its immunoassay development and manufacturing services

Biofortuna is expanding its IVD service portfolio to provide a greater focus on immunoassay design, ...

Read More >

Patients Suspected of Sepsis No Longer Need to Wait 5 Days to Rule out Bloodstream Infection with Momentum Bioscience's ETGA® Technology

A study showing how rapid negative exclusion of blood cultures by a molecular method, Cognitor® Minu...

Read More >

BBI Solutions adds more antibodies to product range

BBI Solutions has continued to invest in its portfolio of antibodies and today announced the launch ...

Read More >